Selank
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Selank is the calming arm of the Russian-school nootropic-peptide pair. Its sister peptide Semax activates and clarifies; Selank smooths the noise. Together they cover the two most common cognitive complaints — I can’t focus and I can’t stop spiraling — with two distinct molecules, each with its own clinical track record.
Structurally, Selank is a synthetic heptapeptide modeled on tuftsin, an endogenous immunomodulatory tetrapeptide. The two extra prolines at the C-terminus stabilize the molecule so it actually survives long enough to work. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia for generalized anxiety disorder.
What’s unusual about Selank — and what makes it interesting as a category-of-one anxiolytic — is that it produces benzodiazepine-equivalent anxiolytic effect without any of the benzodiazepine trade-offs. No sedation. No cognitive blunting. No tolerance. No withdrawal. No dependence risk. In head-to-head clinical comparison against medazepam (a benzodiazepine), Selank matched the anxiolytic effect and beat the benzo on cognitive performance. That’s the entire pitch in one sentence.
What does it do in my body?
Selank works through a triple pathway rather than a single dominant lever. This is part of why the effect profile is so different from SSRIs (which blunt-force inhibit monoamine reuptake) or benzodiazepines (which crank GABA-A wide open):
BDNF upregulation. Selank increases brain-derived neurotrophic factor, which drives synaptic plasticity, neuronal survival, and neurogenesis. This is the mechanistic basis for Selank’s fast onset of anxiolytic effect (1-3 days) — versus SSRIs, which require weeks. Anxiety symptoms that come from a depleted plasticity baseline respond to BDNF restoration much faster than to receptor-level neurotransmitter manipulation.
Enkephalinase inhibition → stabilized endogenous opioid tone. Enkephalinase is the enzyme that breaks down your body’s natural enkephalins — the endogenous opioids that govern mood stability, social bonding, and stress resilience. By slowing that breakdown, Selank lets your own opioid system run at a higher tonic level. No exogenous opioid; no dependence circuitry activated; just less depletion of your own.
Monoamine normalization. Selank modulates serotonin and dopamine tone without the reuptake-blocking pharmacology of SSRIs/SNRIs. The clinical result: anxiolysis without SSRI-class anhedonia or libido suppression — the most common reason people quit SSRIs.
GABA-A: the open mechanistic question. There’s a real contradiction in the published literature here: some sources describe Selank as a positive allosteric modulator of GABA-A at a non-benzodiazepine site (with one report citing a +38% increase in GABA-A binding in mouse brain); others describe it as not a direct GABA-A agonist at all. The contradiction probably resolves into “different sources, different terminology” — the practical outcome is consistent across every source: no benzodiazepine-class adverse profile. No sedation, no tolerance, no withdrawal. Whatever Selank does at GABA-A, it isn’t what Xanax does.
Tuftsin-analog immunomodulation. Selank retains some of tuftsin’s immune activity — enhanced NK cell function, increased interferon production. This is a secondary effect for cognitive/anxiety use, but it’s the basis for the “use with caution in active autoimmune disease or on immunosuppressants” caveat.
How can it help me?
- Best fit: Anxiety, rumination, stress reactivity, sleep-quality issues driven by mental noise; people looking for a non-benzo, non-SSRI anxiolytic that doesn’t blunt cognition
- Where the science stands: 800+ patients across multiple Russian controlled trials including a 60-patient GAD RCT; approved in Russia for generalized anxiety disorder
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Selank is one of the cleanest safety profiles in the entire peptide catalog. Across 800+ patient trial enrollments, no serious adverse events have been reported. The real-world AE cluster:
- Mild nasal irritation from the spray vehicle — the single most common AE. Usually trivial; rotate nostrils, hydrate the nasal mucosa.
- Mild headache in the first few days of a cycle; typically self-resolves.
- Sleep changes if dosed too close to sleep — Selank is mildly activating in some users (despite the anxiolytic effect), so AM/early PM dosing is the standard pattern unless you’re specifically using it for sleep-quality issues.
- No hepatotoxicity, no cardiovascular signals, no documented dependence pattern.
Caution: in active autoimmune conditions or while on immunosuppressant therapy, Selank’s tuftsin-analog immune-modulating effect may interact. Not a hard contraindication, but worth a conversation if you’re managing one of those conditions.
Storage: Refrigerate; protect from light; use within the compounding label window (typically 30-60 days post-reconstitution for the spray form).
Regulatory status: Russia: Approved by the Russian Ministry of Health for generalized anxiety disorder. US: Not FDA-approved for any indication. Not a controlled substance. Sold legally as a research chemical, “not for human consumption.” Not on the WADA prohibited list: notable for athletes. NOT available via 503A compounding pharmacies: on September 29, 2023, FDA added Selank acetate (TP-7) to its Category 2 bulk-drug-substances list, barring it from 503A compounding (Semax and DSIP/Emideltide were added in the same action). One nuance worth tracking: some peptides nominated alongside Selank had their nominations withdrawn in 2024, so the precise current status is worth re-checking — but as it stands Selank is research-channel-only in the US, not compoundable.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Reconstitution + concentration math. Selank is sold either as a pre-made nasal spray (commonly 0.15% = 1.5 mg/mL, or 0.3% / 3 mg/mL) or as a lyophilized powder reconstituted into a metered-dose spray. A pharmaceutical metered spray dispenses ~0.05 mL per actuation; at 1.5 mg/mL that’s 75 mcg per spray (so two sprays ≈ 150 mcg, between-nostril dosing common). exact per-actuation volume across compounded products.
Route. Intranasal spray is the validated route — every published trial used intranasal Selank, and that’s where the human data lives. Subcutaneous is theoretically possible but is not validated clinically; stick with intranasal.
Community-standard protocol (converged across the published RCT dose + Russian clinical practice):
- Standard daily dose: 300-600 mcg/day, split 2-3× (100-200 mcg per dose, typically one spray per nostril per administration).
- Titration: Start at 100-200 mcg/day for the first 7 days; assess; increase if needed. Many users find 300 mcg/day adequate.
- Timing: Morning for daytime anxiety + cognitive support; evening for sleep-quality support. Both are common.
- Cycle (Option A: the RCT pattern): 10-14 consecutive days on / 7-10 days off.
- Cycle (Option B: extended): 28 consecutive days / 2-week break. Trial data showed no tolerance development at day 28.
- No dose escalation required — same dose maintained efficacy across the trial duration. This is a real, distinguishing feature versus the dose-creep typical of benzodiazepines.
TRT compatibility. Selank shows no HPG axis effect, no SHBG effect — it’s safe to stack alongside any standard TRT protocol. Notable for the male performance/anti-aging audience that’s typically running testosterone optimization in parallel.
What should I avoid combining — and what's synergistic?
Stacking. The natural pair is Selank + Semax — calming + activating, used together at reduced individual doses for mixed anxiety-cognitive presentations. Selank also stacks well with foundational support: Glutathione for the oxidative-stress baseline, BPC-157 for systemic anti-inflammatory effects, and GHK-Cu for broader cellular repair signaling.
How can I buy this?
Selank is available from BioLongevity Labs — use code OHM-15 for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
| Class | Synthetic heptapeptide; tuftsin analog (extended Thr-Lys-Pro-Arg with a Pro-Gly-Pro stabilizing tail) |
| Mechanism (one line) | Triple-pathway anxiolytic — BDNF upregulation + enkephalinase inhibition (stabilized endogenous opioid tone) + monoamine (serotonin/dopamine) normalization, without direct benzodiazepine-class GABA-A agonism |
| Route / frequency | Intranasal spray (the validated clinical route); 2-3× daily |
| Half-life | Short in plasma; clinical effect builds over 1-3 days and persists across the cycle |
| Evidence base | 800+ patients across multiple Russian controlled trials including a 60-patient GAD RCT; approved in Russia for generalized anxiety disorder |
| Safety record | Excellent — most common AE is mild nasal irritation from the spray vehicle; no serious AEs in trial literature; no sedation, no tolerance, no withdrawal, no dependence |
| Regulatory status | Russia: approved (generalized anxiety disorder). US: not FDA-approved; sold as a research chemical |
| Alyve product | Not in Alyve’s current launch catalog: flagged as a roadmap candidate |
| Best-fit user | Anxiety, rumination, stress reactivity, sleep-quality issues driven by mental noise; people looking for a non-benzo, non-SSRI anxiolytic that doesn’t blunt cognition |
What it is
Selank is the calming arm of the Russian-school nootropic-peptide pair. Its sister peptide Semax activates and clarifies; Selank smooths the noise. Together they cover the two most common cognitive complaints — I can’t focus and I can’t stop spiraling — with two distinct molecules, each with its own clinical track record.
Structurally, Selank is a synthetic heptapeptide modeled on tuftsin, an endogenous immunomodulatory tetrapeptide. The two extra prolines at the C-terminus stabilize the molecule so it actually survives long enough to work. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia for generalized anxiety disorder.
What’s unusual about Selank — and what makes it interesting as a category-of-one anxiolytic — is that it produces benzodiazepine-equivalent anxiolytic effect without any of the benzodiazepine trade-offs. No sedation. No cognitive blunting. No tolerance. No withdrawal. No dependence risk. In head-to-head clinical comparison against medazepam (a benzodiazepine), Selank matched the anxiolytic effect and beat the benzo on cognitive performance. That’s the entire pitch in one sentence.
How it works
Selank works through a triple pathway rather than a single dominant lever. This is part of why the effect profile is so different from SSRIs (which blunt-force inhibit monoamine reuptake) or benzodiazepines (which crank GABA-A wide open):
BDNF upregulation. Selank increases brain-derived neurotrophic factor, which drives synaptic plasticity, neuronal survival, and neurogenesis. This is the mechanistic basis for Selank’s fast onset of anxiolytic effect (1-3 days) — versus SSRIs, which require weeks. Anxiety symptoms that come from a depleted plasticity baseline respond to BDNF restoration much faster than to receptor-level neurotransmitter manipulation.
Enkephalinase inhibition → stabilized endogenous opioid tone. Enkephalinase is the enzyme that breaks down your body’s natural enkephalins — the endogenous opioids that govern mood stability, social bonding, and stress resilience. By slowing that breakdown, Selank lets your own opioid system run at a higher tonic level. No exogenous opioid; no dependence circuitry activated; just less depletion of your own.
Monoamine normalization. Selank modulates serotonin and dopamine tone without the reuptake-blocking pharmacology of SSRIs/SNRIs. The clinical result: anxiolysis without SSRI-class anhedonia or libido suppression — the most common reason people quit SSRIs.
GABA-A: the open mechanistic question. There’s a real contradiction in the published literature here: some sources describe Selank as a positive allosteric modulator of GABA-A at a non-benzodiazepine site (with one report citing a +38% increase in GABA-A binding in mouse brain); others describe it as not a direct GABA-A agonist at all. The contradiction probably resolves into “different sources, different terminology” — the practical outcome is consistent across every source: no benzodiazepine-class adverse profile. No sedation, no tolerance, no withdrawal. Whatever Selank does at GABA-A, it isn’t what Xanax does.
Tuftsin-analog immunomodulation. Selank retains some of tuftsin’s immune activity — enhanced NK cell function, increased interferon production. This is a secondary effect for cognitive/anxiety use, but it’s the basis for the “use with caution in active autoimmune disease or on immunosuppressants” caveat.
What the research shows
Human / clinical: this is Selank’s strongest tier. Selank is one of the best-evidenced nootropic peptides in the KB at the human-trial level: 800+ patients across multiple controlled Russian trials, including formal RCTs in generalized anxiety disorder. The evidence comes from the Russian-affiliated institutional ecosystem and there’s no independent Western Phase 3 replication — that’s the honest caveat — but the data themselves are real, controlled, and replicated within that ecosystem over a decade-plus.
The landmark trials:
- GAD / neurasthenia vs. medazepam — Zozulia, Neznamov, Siuniakov et al. 2008 (n=62): Selank produced anxiolytic effect similar to medazepam with additional anti-asthenic (anti-fatigue) effects (PMID 18454096). This is the verified anchor for the “matches a benzodiazepine on anxiety” claim.
- vs. phenazepam (head-to-head, tolerability) — Medvedev, Tereshchenko et al. 2014 (n=60): Selank showed anxiolytic + nootropic effects comparable to phenazepam with better tolerability (PMID 25176261). The cognitive edge (benzo slows reaction time, Selank doesn’t) lives in this comparison.
- Combined-therapy optimization — Medvedev, Tereshchenko, Kost et al. 2015 (n=70): adding Selank to phenazepam reduced benzodiazepine side effects while keeping anxiolytic efficacy (PMID 26356395).
- Enkephalinase-inhibition mechanism (human + animal) — Zozulya, Kost et al. 2001 confirmed Selank inhibits enkephalin-degrading enzymes as a basis for its anxiolytic activity (PMID 11550013); Sokolov et al. 2002 replicated this in mice (PMID 12432865).
- Immunomodulation — Uchakina et al. 2008: Selank modulated Th1/Th2 cytokine balance in anxiety-asthenic patients (PMID 18577961); Ershov et al. 2009: antiviral activity against influenza via interferon-alpha induction (PMID 19882898) — the tuftsin-analog arm.
The specific “n=60 GAD RCT, 47% vs 34% HAM-A reduction at 300 mcg 3×/day” figures came from a lower-trust text-aggregation digest and have not been matched to a specific PubMed abstract — keep that exact number tagged until pinned. The verified trial record above supports the same qualitative conclusion (benzodiazepine-equivalent anxiolysis, better cognition/tolerability) on confirmed PMIDs.
Animal / preclinical: first-class evidence supporting the mechanism stack.
- BDNF upregulation in hippocampus + prefrontal cortex.
- Anxiolytic effect in standard rodent models (elevated plus maze, open field) with no sedation/motor impairment.
- Mood stabilization + anti-depressive effects in chronic-stress models.
- Cognitive enhancement on learning/memory tasks.
- Immunomodulatory effects (NK cell, IFN) in immune-challenge models.
Selank vs. Semax: the operational distinction. This is the cleanest single-source decision tree in the KB for the Russian-school cognitive peptides:
| Profile | Selank | Semax |
|---|---|---|
| Effect | Calming + clarifying | Activating + sharpening |
| Best for | Anxiety, rumination, stress reactivity, sleep | Cognitive fog, low drive, attention, motivation |
| Onset of subjective effect | 1-3 days | Hours to days |
| Mechanism focus | BDNF + enkephalin + monoamine normalization | ACTH(4-7) fragment → MC4/MC3 → BDNF/NGF |
| Caveat | Mild nasal irritation; secondary immune effect (caution with autoimmune disease) | Possible elevated baseline anxiety in sensitive users at higher doses |
| Stack | Co-administered at lower doses for mixed presentations — 100 mcg Semax + 100-200 mcg Selank intranasal | (Same — combine at lower doses) |
Stack caveat: there is no controlled human trial of the Semax+Selank combination specifically — Russian clinical use co-administers them but the combination doesn’t have its own trial evidence. Trial each peptide individually before combining.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Route. Intranasal spray is the validated route — every published trial used intranasal Selank, and that’s where the human data lives. Subcutaneous is theoretically possible but is not validated clinically; stick with intranasal.
Reconstitution + concentration math. Selank is sold either as a pre-made nasal spray (commonly 0.15% = 1.5 mg/mL, or 0.3% / 3 mg/mL) or as a lyophilized powder reconstituted into a metered-dose spray. A pharmaceutical metered spray dispenses ~0.05 mL per actuation; at 1.5 mg/mL that’s 75 mcg per spray (so two sprays ≈ 150 mcg, between-nostril dosing common). exact per-actuation volume across compounded products.
Community-standard protocol (converged across the published RCT dose + Russian clinical practice):
- Standard daily dose: 300-600 mcg/day, split 2-3× (100-200 mcg per dose, typically one spray per nostril per administration).
- Titration: Start at 100-200 mcg/day for the first 7 days; assess; increase if needed. Many users find 300 mcg/day adequate.
- Timing: Morning for daytime anxiety + cognitive support; evening for sleep-quality support. Both are common.
- Cycle (Option A: the RCT pattern): 10-14 consecutive days on / 7-10 days off.
- Cycle (Option B: extended): 28 consecutive days / 2-week break. Trial data showed no tolerance development at day 28.
- No dose escalation required — same dose maintained efficacy across the trial duration. This is a real, distinguishing feature versus the dose-creep typical of benzodiazepines.
TRT compatibility. Selank shows no HPG axis effect, no SHBG effect — it’s safe to stack alongside any standard TRT protocol. Notable for the male performance/anti-aging audience that’s typically running testosterone optimization in parallel.
Stacking. The natural pair is Selank + Semax — calming + activating, used together at reduced individual doses for mixed anxiety-cognitive presentations. Selank also stacks well with foundational support: Glutathione for the oxidative-stress baseline, BPC-157 for systemic anti-inflammatory effects, and GHK-Cu for broader cellular repair signaling.
Side effects & management
Selank is one of the cleanest safety profiles in the entire peptide catalog. Across 800+ patient trial enrollments, no serious adverse events have been reported. The real-world AE cluster:
- Mild nasal irritation from the spray vehicle — the single most common AE. Usually trivial; rotate nostrils, hydrate the nasal mucosa.
- Mild headache in the first few days of a cycle; typically self-resolves.
- Sleep changes if dosed too close to sleep — Selank is mildly activating in some users (despite the anxiolytic effect), so AM/early PM dosing is the standard pattern unless you’re specifically using it for sleep-quality issues.
- No hepatotoxicity, no cardiovascular signals, no documented dependence pattern.
Caution: in active autoimmune conditions or while on immunosuppressant therapy, Selank’s tuftsin-analog immune-modulating effect may interact. Not a hard contraindication, but worth a conversation if you’re managing one of those conditions.
Storage: Refrigerate; protect from light; use within the compounding label window (typically 30-60 days post-reconstitution for the spray form).
Regulatory status
Russia: Approved by the Russian Ministry of Health for generalized anxiety disorder. US: Not FDA-approved for any indication. Not a controlled substance. Sold legally as a research chemical, “not for human consumption.” Not on the WADA prohibited list: notable for athletes. NOT available via 503A compounding pharmacies: on September 29, 2023, FDA added Selank acetate (TP-7) to its Category 2 bulk-drug-substances list, barring it from 503A compounding (Semax and DSIP/Emideltide were added in the same action). One nuance worth tracking: some peptides nominated alongside Selank had their nominations withdrawn in 2024, so the precise current status is worth re-checking — but as it stands Selank is research-channel-only in the US, not compoundable.
The Alyve product
Not in Alyve’s current launch catalog: flagged as a roadmap candidate. Selank is on the catalog-expansion shortlist alongside Semax as the natural Russian-nootropic-pair offering. The format that matches the clinical convention is a pre-made intranasal spray (0.15% or 0.3%).
The Alyve trust story still anchors every peptide decision: US-manufactured, third-party Freedom Diagnostics COAs, >99% purity verified across the launch catalog, identity-confirmed by HPLC-UV + LC-MS. The supply-chain story matters disproportionately for the Russian-school peptides specifically — counterfeit Selank and Semax are common in the gray market, and the typical buyer has no easy way to verify what they’re getting. A verified-COA vendor isn’t a luxury for this category; it’s the whole reason to buy from a vendor rather than a forum link.
Where to buy Selank today. Selank isn’t an Alyve SKU yet, but it’s now carried by BioLongevity Labs, a verified OHM affiliate partner with third-party COA testing: use code OHM-15 for 15% off. As with Semax, the Russian-nootropic category is gray-market-heavy and counterfeits are common, so the thing that decides whether a protocol works is identity-confirmed, COA-tested product — buy from a tested source. A peptide-literate clinician is also a solid route (provider directory).
Sources
- primary source for mechanism (triple pathway), the 60-patient GAD RCT, the medazepam head-to-head, dosing protocols, Selank-vs-Semax distinction, TRT compatibility, the GABA-A mechanism contradiction.
- Durst’s clinical-practice Selank-vs-Semax framing (calming/anxiety vs. activating/focus), intranasal-as-standard confirmation.
- Selank B/green + SECONDARY sleep grading.
- thepeptidelist.com directory entry; source of the now-verified Russian RCT PMIDs (18454096, 25176261, 26356395), the enkephalinase-mechanism PMIDs (11550013, 12432865), and the FDA-Category-2 (compounding-restricted) status flag.
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Related: Semax · Cognitive peptides cluster — Dihexa, Pinealon, Cortagen · Glutathione · BPC-157 · GHK-Cu.
Sources & references
- primary source for mechanism (triple pathway), the 60-patient GAD RCT, the medazepam head-to-head, dosing protocols, Selank-vs-Semax distinction, TRT compatibility, the GABA-A mechanism contradiction.
- Durst’s clinical-practice Selank-vs-Semax framing (calming/anxiety vs. activating/focus), intranasal-as-standard confirmation.
- Selank B/green + SECONDARY sleep grading.
- thepeptidelist.com directory entry; source of the now-verified Russian RCT PMIDs (18454096, 25176261, 26356395), the enkephalinase-mechanism PMIDs (11550013, 12432865), and the FDA-Category-2 (compounding-restricted) status flag.
- FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Related: Semax · Cognitive peptides cluster — Dihexa, Pinealon, Cortagen · Glutathione · BPC-157 · GHK-Cu.